Company Reports Q4 Revenue of $397.6M, Exceeding Expectations
Reports Q4 revenue $397.6M, consensus $390.0M. "2025 was a year of broad-based execution and disciplined investment, with results that exceeded our expectations across resident, revenue, and Adjusted EBITDA growth," said Fred Burke, CEO. "These results underscore the scalability of our platform and the dedication of our teams, who continue to deliver high-quality service and meaningful value to the residents and facility partners we serve. We exited the year with strong momentum and are accordingly raising our outlook for 2026 Adjusted EBITDA in a measured manner, consistent with our philosophy of guiding to what we can clearly see. A portion of the upside we experienced in the fourth quarter relative to our prior guidance reflects favorable payor dynamics and normal quarter-to-quarter variability, which we have not incorporated into our outlook. We view the underlying run rate of the business exiting 2025 as generating approximately $110 million of Adjusted EBITDA, and are raising our 2026 outlook on that basis. As we enter the first quarter under the initial phase of new IRA drug pricing changes, we are maintaining our 2026 revenue outlook provided in mid-January. We remain confident in the durability of our operating model and our ability to deliver sustained, long-term value for our shareholders."
Trade with 70% Backtested Accuracy
Analyst Views on GRDN
About GRDN
About the author

- Significant Revenue Growth: In Q4 2025, Guardian Pharmacy Services reported revenue of $397.6 million, a 17% year-over-year increase, with organic growth reaching 12%, demonstrating the company's strong performance in acquiring new residents and increasing script volume, thereby solidifying its market position.
- Adjusted EBITDA Surge: The company achieved a 53% year-over-year increase in adjusted EBITDA to $39.5 million, with margins expanding to 9.9%, reflecting successful operational efficiency and cost control, which enhances the sustainability of future profitability.
- Strong Cash Flow: As of Q4 2025, the company's cash balance rose to $66 million, up from $36 million in Q3, indicating robust cash generation capabilities that support future investments and acquisitions.
- Optimistic 2026 Outlook: The company raised its 2026 adjusted EBITDA guidance to $120 million to $124 million, reflecting confidence in ongoing growth drivers, while maintaining revenue expectations between $1.4 billion and $1.42 billion, showcasing adaptability to new pricing policies.
- Strong Earnings Report: Guardian Pharmacy Services reported a Q4 GAAP EPS of $0.37, beating expectations by $0.15, which demonstrates robust profitability growth and boosts investor confidence.
- Revenue Growth: The company achieved Q4 revenue of $397.6 million, exceeding market expectations by $7.56 million, reflecting its competitive position and sustained customer demand in the market.
- 2026 Outlook: The company raised its adjusted EBITDA guidance for FY 2026 to between $120 million and $124 million, up from the previous range of $115 million to $118 million, indicating management's optimistic outlook for future performance.
- Stable Revenue Expectations: The revenue forecast for FY 2026 remains between $1.40 billion and $1.42 billion, showcasing the company's confidence in revenue stability, which is expected to continue attracting investor interest.
- Significant Revenue Growth: Guardian Pharmacy Services reported fourth-quarter revenue of $397.6 million, a 17% year-over-year increase with organic growth of 12%, indicating strong performance in the long-term care pharmacy market and potential for increased market share.
- Substantial Net Income Increase: The company achieved a net income of $21.3 million in Q4, up 81% from $11.8 million in the prior year, reflecting successful cost control and operational efficiency, which bolsters investor confidence.
- Adjusted EBITDA Guidance Raised: Guardian raised its 2026 Adjusted EBITDA outlook to $120 million to $124 million, up from the previous guidance of $115 million to $118 million, signaling management's optimistic expectations for future performance.
- Vaccine Prescription Volume Growth: The company saw a 9% year-over-year increase in vaccine prescription volumes in 2025, vaccinating over 120,000 residents, demonstrating its commitment to public health services while enhancing brand image and customer loyalty.
- Conference Schedule: Guardian Pharmacy Services will present at the Raymond James Institutional Investors Conference on March 2 at 1:40 p.m. Eastern Time, showcasing its expertise in long-term care pharmacy services.
- Webcast Availability: The session will feature a live audio webcast accessible via the company's website, with a replay available for 90 days post-event, ensuring that investors who cannot attend live can still access the information.
- Company Background: Guardian Pharmacy Services is one of the nation's leading long-term care pharmacy service providers, dedicated to enhancing care quality and improving medication adherence through partnerships with long-term care facilities, ultimately reducing care costs.
- Service Coverage: As of September 30, 2025, Guardian operates over 50 pharmacies nationwide, serving nearly 204,000 residents, demonstrating its significant impact and commitment to the long-term care market.

- Earnings Release Schedule: Guardian Pharmacy Services will announce its fourth quarter and full-year 2025 financial results after market close on March 11, 2026, providing investors with critical financial performance data to assess the company's operational status.
- Conference Call Details: Management will host a conference call at 4:30 p.m. Eastern Time to discuss the financial results, allowing investors to participate via audio webcast or designated phone numbers, ensuring transparency and timeliness of information.
- Replay Availability: A replay of the call will be available for approximately 60 days after its conclusion, enabling investors who could not attend in real-time to access important information, thereby enhancing communication between the company and its investors.
- Company Background: Guardian Pharmacy Services is one of the nation's leading long-term care pharmacy service providers, dedicated to partnering with long-term care facilities to deliver medications and technology-enabled services aimed at reducing care costs and improving clinical outcomes, serving approximately 204,000 residents.








